From research to practice: bridging the implementation gap on the use of tranexamic acid in total knee arthroplasty.

ABSTRACT:

Background

The use of intravenous tranexamic acid (TXA), an antifibrinolytic agent, has been shown to effectively reduce total blood loss and transfusion rates in total knee arthroplasty (TKA). The aim of this paper is to evaluate the implementation lag and clinical uptake of the use of TXA for primary TKA after publication of two landmark studies. Additionally, it assessed the efficacy of TXA use in TKA in reducing post-operative blood transfusions and hospital length of stay (LOS).

Methods

A total of 763 patients aged over 18 years of age underwent primary TKA at a level 4 metropolitan hospital in Australia between January 2011 and December 2017. Primary outcome measure was use of TXA at operative induction. Secondary outcome measures were post-operative blood transfusion,

SUBMITTER: Pfister RM 

PROVIDER: S-EPMC11780759 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature